Hanrahan, T.P.; Chan, R.; Tassone, D.; Ding, N.S.; Basnayake, C.; Schulberg, J.; Vasudevan, A.; Kamm, M.; De Gregorio, M.; van Langenberg, D.R.;
et al. Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study. Future Pharmacol. 2022, 2, 669-680.
https://doi.org/10.3390/futurepharmacol2040041
AMA Style
Hanrahan TP, Chan R, Tassone D, Ding NS, Basnayake C, Schulberg J, Vasudevan A, Kamm M, De Gregorio M, van Langenberg DR,
et al. Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study. Future Pharmacology. 2022; 2(4):669-680.
https://doi.org/10.3390/futurepharmacol2040041
Chicago/Turabian Style
Hanrahan, Timothy P., Robbie Chan, Daniel Tassone, Nik S. Ding, Chamara Basnayake, Julien Schulberg, Abhinav Vasudevan, Michael Kamm, Michael De Gregorio, Daniel R. van Langenberg,
and et al. 2022. "Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study" Future Pharmacology 2, no. 4: 669-680.
https://doi.org/10.3390/futurepharmacol2040041
APA Style
Hanrahan, T. P., Chan, R., Tassone, D., Ding, N. S., Basnayake, C., Schulberg, J., Vasudevan, A., Kamm, M., De Gregorio, M., van Langenberg, D. R., & Niewiadomski, O.
(2022). Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study. Future Pharmacology, 2(4), 669-680.
https://doi.org/10.3390/futurepharmacol2040041